Literature DB >> 17460396

Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?

Michael Hertl, Rüdiger Eming, Luca Borradori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17460396     DOI： 10.1159/000100876

Source DB:  PubMed          Journal:  Dermatology        ISSN： 1018-8665            Impact factor:   5.366


× No keyword cloud information.
  3 in total

Review 1.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

2.  Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris.

Authors:  Ralf Müller; Nicolas Hunzelmann; Vera Baur; Guido Siebenhaar; Elke Wenzel; Rüdiger Eming; Andrea Niedermeier; Philippe Musette; Pascal Joly; Michael Hertl
Journal:  Dermatol Res Pract       Date:  2010-06-30

3.  Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.

Authors:  Isabela Soubhia Corral; Thais Helena Proença de Freitas; Renata Telles Rudge de Aquino; Daniella Abbruzzini S Koller; Maria Elisa Ruffolo Magliari; Helena Muller
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.